ROCEPHIN KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN KIT (ROCEPHIN KIT).
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged primarily in urine (33-67%) and bile (up to 40%). |
| Excretion | Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor). |
| Half-life | Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | 85-95%, primarily to albumin. |
| Volume of Distribution | 0.12-0.14 L/kg (low, indicating limited extravascular distribution, but adequate for common infections). |
| Bioavailability | IM: 100% (complete absorption). |
| Onset of Action | IV: rapid within 15-30 minutes; IM: 1-2 hours. |
| Duration of Action | Approximately 24 hours due to prolonged half-life, allowing once-daily dosing for most infections. |
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl <10 mL/min: 1 g IV or IM every 24 hours. No adjustment needed for CrCl ≥10 mL/min. |
| Liver impairment | No specific Child-Pugh based adjustments required. Caution in severe hepatic impairment with concurrent renal impairment. |
| Pediatric use | Neonates (0-28 days): 50 mg/kg IV or IM once daily. Infants and children (1 month-12 years): 50-100 mg/kg IV or IM once daily, max 4 g/day. For meningitis: 100 mg/kg IV once daily, max 4 g/day. |
| Geriatric use | Same as adult dosing. Monitor renal function; adjust dose if CrCl <10 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN KIT (ROCEPHIN KIT).
| Breastfeeding | Ceftriaxone is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.03-0.05 based on limited data. The amount ingested by the infant is less than 4% of the maternal therapeutic dose and is unlikely to cause adverse effects. Breastfeeding is considered compatible during maternal ceftriaxone therapy. However, potential for alteration of infant gut flora and direct GI effects (e.g., diarrhea, candidiasis) should be considered. No dose adjustment is needed for the nursing infant. |
| Teratogenic Risk | Ceftriaxone (Rocephin) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. In the first trimester, the risk is considered low based on available human data. In the second and third trimesters, ceftriaxone crosses the placenta and achieves therapeutic levels in fetal serum and amniotic fluid. No specific congenital anomalies have been consistently associated. However, caution is advised in preterm infants due to risk of bilirubin displacement, but this is a neonatal concern, not fetal. Overall, the drug should be used during pregnancy only if clearly needed. |
■ FDA Black Box Warning
Ceftriaxone is contraindicated in neonates (≤28 days old) if they require calcium-containing IV solutions due to risk of precipitation of ceftriaxone-calcium salt in lungs and kidneys.
| Serious Effects |
["Hypersensitivity to ceftriaxone, any cephalosporin, or any component of the formulation.","Neonates (≤28 days) requiring calcium-containing IV solutions (e.g., Ringer's lactate, parenteral nutrition)."]
| Precautions | ["Hypersensitivity reactions (including anaphylaxis) may occur, especially in patients with penicillin or other beta-lactam allergies.","C. difficile-associated diarrhea (CDAD) may occur.","Hemolytic anemia (immune-mediated) reported, monitor for signs.","Concomitant use with calcium-containing IV solutions contraindicated in neonates; caution in other age groups due to precipitation risk.","Biliary pseudolithiasis (reversible) may occur with high doses.","May prolong prothrombin time; monitor in patients with coagulation disorders or on anticoagulants."] |
Loading safety data…
| Fetal Monitoring | Maternal: Renal function, hepatic function, and blood counts should be monitored during prolonged therapy due to potential for neutropenia, thrombocytopenia, or elevated liver enzymes. Monitor for signs of hypersensitivity reactions. Fetal: Standard prenatal monitoring is sufficient; no specific fetal monitoring is required due to ceftriaxone use. Neonatal: In infants born to mothers treated near term, monitor for signs of jaundice or bilirubin encephalopathy, especially in preterm or hyperbilirubinemic infants, due to ceftriaxone's potential to displace bilirubin from albumin. |
| Fertility Effects | Ceftriaxone has not been associated with adverse effects on fertility in animal studies. No human data suggest impairment of male or female reproductive function. However, like other cephalosporins, it may cause transient reduction in sperm motility or count in some studies, but clinical significance is unclear. Overall, no significant impact on fertility is expected. |